Frontiers in Immunology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2092291, encodeId=dacb20922915f, content=这个杂志吃相有点难看了，今年发文量已经9000篇，大概率要进年底的中科院预警, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Fri Oct 07 15:59:52 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052882, encodeId=e2fb10528824a, content=偏重的研究方向：免疫 经验分享：有最近投这个杂志板块的吗？9月6日提交含原始数据后，过了12天了，还没有看到有EA（editor assignment）的消息。一般大概等多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9215432780, createdName=ms7000000299539143, createdTime=Sat Sep 18 20:25:24 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799157, encodeId=ba6be991570e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：请问各位大佬，交完出版费大概多久见刊呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92185275664, createdName=14830f0fm18(暂无昵称), createdTime=Fri Jun 19 11:56:42 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009867, encodeId=2723100986ea9, content=我想问一下大家，Independent Review时，下面出现的那个review is onging代表什么，我的已经出现了两次了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Sat Aug 21 01:00:16 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217603, encodeId=6a20121e60358, content=偏重的研究方向：自身免疫 经验分享：重新提交原始数据之后一直处于初始阶段，老铁们，这大概要持续多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Sat May 07 12:41:08 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055459, encodeId=986e1055459c4, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫;先天免疫 经验分享：给大家分享一下我的投稿 Received date: 23 Aug 2021 Editorial assignment start date: 23 Aug 2021 Independent review start date: 04 Sep 2021 Interactive review activated date: 11 Sep 2021 Review finalized date: 25 Sep 2021 Final validation date: 27 Sep 2021 27号接收的。从投稿到接收一个多月。编辑很负责，外审专家提的意见也很中肯，稍微补了点实验，两轮修改之后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04235081194, createdName=华灯初上&, createdTime=Mon Sep 27 19:44:41 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198618, encodeId=6492119861813, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：抗病毒免疫 经验分享：三个审稿人，两个直接endorsed，一个直接rejected，从3. Independent Review直接跳到5. Review Finalized，都没有4. Interactive Review阶段。现在状态The Associate Editor is evaluating any revisions made to the manuscript to take a final decision.这个杂志审稿这么刺激啊，真是尴尬啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Wed Mar 02 10:05:47 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192212, encodeId=53a31192212da, content=各位友友，这个杂志还收不收纯生信呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/1d3a85981f6341c685aa69f9c27013bd/bc9a63edcff04dfda9c41946c5223f0b.jpg, createdBy=c7c95614650, createdName=ms2000001076054986, createdTime=Fri Feb 11 10:05:04 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212988, encodeId=70ff1212988fa, content=偏重的研究方向：免疫;肿瘤 经验分享：请问各位，目前是返修状态，返修4.24到期，一共五个审稿人，一个是rejected，一个endorsed，一个active，两个pending（4月20号到期），如果我21号提交修回稿件之后，这两个人还没有给意见的话，会取消审稿吗？取消后还会找其他人来审稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210909/7146f1426c1e49bbb98d94637759e71f/7d17fd3269ca410d895702092f504459.jpg, createdBy=ac155115075, createdName=一只虫虫, createdTime=Wed Apr 20 22:34:55 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213503, encodeId=58db1213503e6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫治疗 经验分享：26 Feb 2022 submitted 4 Apr 2022 interview review 21 Apr 2022 review finalized 22 Apr 2022 accepted 科研小白的第一篇SCI。两位审稿专家，第1位8条意见，第2位4条意见，建议刚开始推荐审稿人，减少分配审稿人的时间，希望大家都能如愿以偿！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed025273112, createdName=14828bdem32暂无昵称, createdTime=Fri Apr 22 19:59:27 CST 2022, time=2022-04-22, status=1, ipAttribution=)]

2022-10-07 H·D·E

这个杂志吃相有点难看了，今年发文量已经9000篇，大概率要进年底的中科院预警

56 17

展开17条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092291, encodeId=dacb20922915f, content=这个杂志吃相有点难看了，今年发文量已经9000篇，大概率要进年底的中科院预警, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Fri Oct 07 15:59:52 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052882, encodeId=e2fb10528824a, content=偏重的研究方向：免疫 经验分享：有最近投这个杂志板块的吗？9月6日提交含原始数据后，过了12天了，还没有看到有EA（editor assignment）的消息。一般大概等多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9215432780, createdName=ms7000000299539143, createdTime=Sat Sep 18 20:25:24 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799157, encodeId=ba6be991570e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：请问各位大佬，交完出版费大概多久见刊呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92185275664, createdName=14830f0fm18(暂无昵称), createdTime=Fri Jun 19 11:56:42 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009867, encodeId=2723100986ea9, content=我想问一下大家，Independent Review时，下面出现的那个review is onging代表什么，我的已经出现了两次了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Sat Aug 21 01:00:16 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217603, encodeId=6a20121e60358, content=偏重的研究方向：自身免疫 经验分享：重新提交原始数据之后一直处于初始阶段，老铁们，这大概要持续多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Sat May 07 12:41:08 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055459, encodeId=986e1055459c4, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫;先天免疫 经验分享：给大家分享一下我的投稿 Received date: 23 Aug 2021 Editorial assignment start date: 23 Aug 2021 Independent review start date: 04 Sep 2021 Interactive review activated date: 11 Sep 2021 Review finalized date: 25 Sep 2021 Final validation date: 27 Sep 2021 27号接收的。从投稿到接收一个多月。编辑很负责，外审专家提的意见也很中肯，稍微补了点实验，两轮修改之后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04235081194, createdName=华灯初上&, createdTime=Mon Sep 27 19:44:41 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198618, encodeId=6492119861813, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：抗病毒免疫 经验分享：三个审稿人，两个直接endorsed，一个直接rejected，从3. Independent Review直接跳到5. Review Finalized，都没有4. Interactive Review阶段。现在状态The Associate Editor is evaluating any revisions made to the manuscript to take a final decision.这个杂志审稿这么刺激啊，真是尴尬啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Wed Mar 02 10:05:47 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192212, encodeId=53a31192212da, content=各位友友，这个杂志还收不收纯生信呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/1d3a85981f6341c685aa69f9c27013bd/bc9a63edcff04dfda9c41946c5223f0b.jpg, createdBy=c7c95614650, createdName=ms2000001076054986, createdTime=Fri Feb 11 10:05:04 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212988, encodeId=70ff1212988fa, content=偏重的研究方向：免疫;肿瘤 经验分享：请问各位，目前是返修状态，返修4.24到期，一共五个审稿人，一个是rejected，一个endorsed，一个active，两个pending（4月20号到期），如果我21号提交修回稿件之后，这两个人还没有给意见的话，会取消审稿吗？取消后还会找其他人来审稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210909/7146f1426c1e49bbb98d94637759e71f/7d17fd3269ca410d895702092f504459.jpg, createdBy=ac155115075, createdName=一只虫虫, createdTime=Wed Apr 20 22:34:55 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213503, encodeId=58db1213503e6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫治疗 经验分享：26 Feb 2022 submitted 4 Apr 2022 interview review 21 Apr 2022 review finalized 22 Apr 2022 accepted 科研小白的第一篇SCI。两位审稿专家，第1位8条意见，第2位4条意见，建议刚开始推荐审稿人，减少分配审稿人的时间，希望大家都能如愿以偿！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed025273112, createdName=14828bdem32暂无昵称, createdTime=Fri Apr 22 19:59:27 CST 2022, time=2022-04-22, status=1, ipAttribution=)]

2021-09-18 ms7000000299539143

偏重的研究方向：免疫
经验分享：有最近投这个杂志板块的吗？9月6日提交含原始数据后，过了12天了，还没有看到有EA（editor assignment）的消息。一般大概等多久呢？

83 17

展开17条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092291, encodeId=dacb20922915f, content=这个杂志吃相有点难看了，今年发文量已经9000篇，大概率要进年底的中科院预警, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Fri Oct 07 15:59:52 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052882, encodeId=e2fb10528824a, content=偏重的研究方向：免疫 经验分享：有最近投这个杂志板块的吗？9月6日提交含原始数据后，过了12天了，还没有看到有EA（editor assignment）的消息。一般大概等多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9215432780, createdName=ms7000000299539143, createdTime=Sat Sep 18 20:25:24 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799157, encodeId=ba6be991570e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：请问各位大佬，交完出版费大概多久见刊呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92185275664, createdName=14830f0fm18(暂无昵称), createdTime=Fri Jun 19 11:56:42 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009867, encodeId=2723100986ea9, content=我想问一下大家，Independent Review时，下面出现的那个review is onging代表什么，我的已经出现了两次了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Sat Aug 21 01:00:16 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217603, encodeId=6a20121e60358, content=偏重的研究方向：自身免疫 经验分享：重新提交原始数据之后一直处于初始阶段，老铁们，这大概要持续多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Sat May 07 12:41:08 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055459, encodeId=986e1055459c4, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫;先天免疫 经验分享：给大家分享一下我的投稿 Received date: 23 Aug 2021 Editorial assignment start date: 23 Aug 2021 Independent review start date: 04 Sep 2021 Interactive review activated date: 11 Sep 2021 Review finalized date: 25 Sep 2021 Final validation date: 27 Sep 2021 27号接收的。从投稿到接收一个多月。编辑很负责，外审专家提的意见也很中肯，稍微补了点实验，两轮修改之后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04235081194, createdName=华灯初上&, createdTime=Mon Sep 27 19:44:41 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198618, encodeId=6492119861813, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：抗病毒免疫 经验分享：三个审稿人，两个直接endorsed，一个直接rejected，从3. Independent Review直接跳到5. Review Finalized，都没有4. Interactive Review阶段。现在状态The Associate Editor is evaluating any revisions made to the manuscript to take a final decision.这个杂志审稿这么刺激啊，真是尴尬啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Wed Mar 02 10:05:47 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192212, encodeId=53a31192212da, content=各位友友，这个杂志还收不收纯生信呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/1d3a85981f6341c685aa69f9c27013bd/bc9a63edcff04dfda9c41946c5223f0b.jpg, createdBy=c7c95614650, createdName=ms2000001076054986, createdTime=Fri Feb 11 10:05:04 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212988, encodeId=70ff1212988fa, content=偏重的研究方向：免疫;肿瘤 经验分享：请问各位，目前是返修状态，返修4.24到期，一共五个审稿人，一个是rejected，一个endorsed，一个active，两个pending（4月20号到期），如果我21号提交修回稿件之后，这两个人还没有给意见的话，会取消审稿吗？取消后还会找其他人来审稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210909/7146f1426c1e49bbb98d94637759e71f/7d17fd3269ca410d895702092f504459.jpg, createdBy=ac155115075, createdName=一只虫虫, createdTime=Wed Apr 20 22:34:55 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213503, encodeId=58db1213503e6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫治疗 经验分享：26 Feb 2022 submitted 4 Apr 2022 interview review 21 Apr 2022 review finalized 22 Apr 2022 accepted 科研小白的第一篇SCI。两位审稿专家，第1位8条意见，第2位4条意见，建议刚开始推荐审稿人，减少分配审稿人的时间，希望大家都能如愿以偿！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed025273112, createdName=14828bdem32暂无昵称, createdTime=Fri Apr 22 19:59:27 CST 2022, time=2022-04-22, status=1, ipAttribution=)]

2020-06-19 14830f0fm18(暂无昵称)

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤免疫
经验分享：请问各位大佬，交完出版费大概多久见刊呀？

124 17

展开17条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092291, encodeId=dacb20922915f, content=这个杂志吃相有点难看了，今年发文量已经9000篇，大概率要进年底的中科院预警, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Fri Oct 07 15:59:52 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052882, encodeId=e2fb10528824a, content=偏重的研究方向：免疫 经验分享：有最近投这个杂志板块的吗？9月6日提交含原始数据后，过了12天了，还没有看到有EA（editor assignment）的消息。一般大概等多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9215432780, createdName=ms7000000299539143, createdTime=Sat Sep 18 20:25:24 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799157, encodeId=ba6be991570e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：请问各位大佬，交完出版费大概多久见刊呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92185275664, createdName=14830f0fm18(暂无昵称), createdTime=Fri Jun 19 11:56:42 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009867, encodeId=2723100986ea9, content=我想问一下大家，Independent Review时，下面出现的那个review is onging代表什么，我的已经出现了两次了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Sat Aug 21 01:00:16 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217603, encodeId=6a20121e60358, content=偏重的研究方向：自身免疫 经验分享：重新提交原始数据之后一直处于初始阶段，老铁们，这大概要持续多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Sat May 07 12:41:08 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055459, encodeId=986e1055459c4, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫;先天免疫 经验分享：给大家分享一下我的投稿 Received date: 23 Aug 2021 Editorial assignment start date: 23 Aug 2021 Independent review start date: 04 Sep 2021 Interactive review activated date: 11 Sep 2021 Review finalized date: 25 Sep 2021 Final validation date: 27 Sep 2021 27号接收的。从投稿到接收一个多月。编辑很负责，外审专家提的意见也很中肯，稍微补了点实验，两轮修改之后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04235081194, createdName=华灯初上&, createdTime=Mon Sep 27 19:44:41 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198618, encodeId=6492119861813, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：抗病毒免疫 经验分享：三个审稿人，两个直接endorsed，一个直接rejected，从3. Independent Review直接跳到5. Review Finalized，都没有4. Interactive Review阶段。现在状态The Associate Editor is evaluating any revisions made to the manuscript to take a final decision.这个杂志审稿这么刺激啊，真是尴尬啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Wed Mar 02 10:05:47 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192212, encodeId=53a31192212da, content=各位友友，这个杂志还收不收纯生信呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/1d3a85981f6341c685aa69f9c27013bd/bc9a63edcff04dfda9c41946c5223f0b.jpg, createdBy=c7c95614650, createdName=ms2000001076054986, createdTime=Fri Feb 11 10:05:04 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212988, encodeId=70ff1212988fa, content=偏重的研究方向：免疫;肿瘤 经验分享：请问各位，目前是返修状态，返修4.24到期，一共五个审稿人，一个是rejected，一个endorsed，一个active，两个pending（4月20号到期），如果我21号提交修回稿件之后，这两个人还没有给意见的话，会取消审稿吗？取消后还会找其他人来审稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210909/7146f1426c1e49bbb98d94637759e71f/7d17fd3269ca410d895702092f504459.jpg, createdBy=ac155115075, createdName=一只虫虫, createdTime=Wed Apr 20 22:34:55 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213503, encodeId=58db1213503e6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫治疗 经验分享：26 Feb 2022 submitted 4 Apr 2022 interview review 21 Apr 2022 review finalized 22 Apr 2022 accepted 科研小白的第一篇SCI。两位审稿专家，第1位8条意见，第2位4条意见，建议刚开始推荐审稿人，减少分配审稿人的时间，希望大家都能如愿以偿！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed025273112, createdName=14828bdem32暂无昵称, createdTime=Fri Apr 22 19:59:27 CST 2022, time=2022-04-22, status=1, ipAttribution=)]

2021-08-21 骞骞F文章

我想问一下大家，Independent Review时，下面出现的那个review is onging代表什么，我的已经出现了两次了。

54 16

展开16条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092291, encodeId=dacb20922915f, content=这个杂志吃相有点难看了，今年发文量已经9000篇，大概率要进年底的中科院预警, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Fri Oct 07 15:59:52 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052882, encodeId=e2fb10528824a, content=偏重的研究方向：免疫 经验分享：有最近投这个杂志板块的吗？9月6日提交含原始数据后，过了12天了，还没有看到有EA（editor assignment）的消息。一般大概等多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9215432780, createdName=ms7000000299539143, createdTime=Sat Sep 18 20:25:24 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799157, encodeId=ba6be991570e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：请问各位大佬，交完出版费大概多久见刊呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92185275664, createdName=14830f0fm18(暂无昵称), createdTime=Fri Jun 19 11:56:42 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009867, encodeId=2723100986ea9, content=我想问一下大家，Independent Review时，下面出现的那个review is onging代表什么，我的已经出现了两次了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Sat Aug 21 01:00:16 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217603, encodeId=6a20121e60358, content=偏重的研究方向：自身免疫 经验分享：重新提交原始数据之后一直处于初始阶段，老铁们，这大概要持续多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Sat May 07 12:41:08 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055459, encodeId=986e1055459c4, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫;先天免疫 经验分享：给大家分享一下我的投稿 Received date: 23 Aug 2021 Editorial assignment start date: 23 Aug 2021 Independent review start date: 04 Sep 2021 Interactive review activated date: 11 Sep 2021 Review finalized date: 25 Sep 2021 Final validation date: 27 Sep 2021 27号接收的。从投稿到接收一个多月。编辑很负责，外审专家提的意见也很中肯，稍微补了点实验，两轮修改之后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04235081194, createdName=华灯初上&, createdTime=Mon Sep 27 19:44:41 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198618, encodeId=6492119861813, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：抗病毒免疫 经验分享：三个审稿人，两个直接endorsed，一个直接rejected，从3. Independent Review直接跳到5. Review Finalized，都没有4. Interactive Review阶段。现在状态The Associate Editor is evaluating any revisions made to the manuscript to take a final decision.这个杂志审稿这么刺激啊，真是尴尬啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Wed Mar 02 10:05:47 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192212, encodeId=53a31192212da, content=各位友友，这个杂志还收不收纯生信呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/1d3a85981f6341c685aa69f9c27013bd/bc9a63edcff04dfda9c41946c5223f0b.jpg, createdBy=c7c95614650, createdName=ms2000001076054986, createdTime=Fri Feb 11 10:05:04 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212988, encodeId=70ff1212988fa, content=偏重的研究方向：免疫;肿瘤 经验分享：请问各位，目前是返修状态，返修4.24到期，一共五个审稿人，一个是rejected，一个endorsed，一个active，两个pending（4月20号到期），如果我21号提交修回稿件之后，这两个人还没有给意见的话，会取消审稿吗？取消后还会找其他人来审稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210909/7146f1426c1e49bbb98d94637759e71f/7d17fd3269ca410d895702092f504459.jpg, createdBy=ac155115075, createdName=一只虫虫, createdTime=Wed Apr 20 22:34:55 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213503, encodeId=58db1213503e6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫治疗 经验分享：26 Feb 2022 submitted 4 Apr 2022 interview review 21 Apr 2022 review finalized 22 Apr 2022 accepted 科研小白的第一篇SCI。两位审稿专家，第1位8条意见，第2位4条意见，建议刚开始推荐审稿人，减少分配审稿人的时间，希望大家都能如愿以偿！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed025273112, createdName=14828bdem32暂无昵称, createdTime=Fri Apr 22 19:59:27 CST 2022, time=2022-04-22, status=1, ipAttribution=)]

2022-05-07 丿柚子

偏重的研究方向：自身免疫
经验分享：重新提交原始数据之后一直处于初始阶段，老铁们，这大概要持续多久？

182 15

展开15条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092291, encodeId=dacb20922915f, content=这个杂志吃相有点难看了，今年发文量已经9000篇，大概率要进年底的中科院预警, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Fri Oct 07 15:59:52 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052882, encodeId=e2fb10528824a, content=偏重的研究方向：免疫 经验分享：有最近投这个杂志板块的吗？9月6日提交含原始数据后，过了12天了，还没有看到有EA（editor assignment）的消息。一般大概等多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9215432780, createdName=ms7000000299539143, createdTime=Sat Sep 18 20:25:24 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799157, encodeId=ba6be991570e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：请问各位大佬，交完出版费大概多久见刊呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92185275664, createdName=14830f0fm18(暂无昵称), createdTime=Fri Jun 19 11:56:42 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009867, encodeId=2723100986ea9, content=我想问一下大家，Independent Review时，下面出现的那个review is onging代表什么，我的已经出现了两次了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Sat Aug 21 01:00:16 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217603, encodeId=6a20121e60358, content=偏重的研究方向：自身免疫 经验分享：重新提交原始数据之后一直处于初始阶段，老铁们，这大概要持续多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Sat May 07 12:41:08 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055459, encodeId=986e1055459c4, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫;先天免疫 经验分享：给大家分享一下我的投稿 Received date: 23 Aug 2021 Editorial assignment start date: 23 Aug 2021 Independent review start date: 04 Sep 2021 Interactive review activated date: 11 Sep 2021 Review finalized date: 25 Sep 2021 Final validation date: 27 Sep 2021 27号接收的。从投稿到接收一个多月。编辑很负责，外审专家提的意见也很中肯，稍微补了点实验，两轮修改之后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04235081194, createdName=华灯初上&, createdTime=Mon Sep 27 19:44:41 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198618, encodeId=6492119861813, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：抗病毒免疫 经验分享：三个审稿人，两个直接endorsed，一个直接rejected，从3. Independent Review直接跳到5. Review Finalized，都没有4. Interactive Review阶段。现在状态The Associate Editor is evaluating any revisions made to the manuscript to take a final decision.这个杂志审稿这么刺激啊，真是尴尬啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Wed Mar 02 10:05:47 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192212, encodeId=53a31192212da, content=各位友友，这个杂志还收不收纯生信呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/1d3a85981f6341c685aa69f9c27013bd/bc9a63edcff04dfda9c41946c5223f0b.jpg, createdBy=c7c95614650, createdName=ms2000001076054986, createdTime=Fri Feb 11 10:05:04 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212988, encodeId=70ff1212988fa, content=偏重的研究方向：免疫;肿瘤 经验分享：请问各位，目前是返修状态，返修4.24到期，一共五个审稿人，一个是rejected，一个endorsed，一个active，两个pending（4月20号到期），如果我21号提交修回稿件之后，这两个人还没有给意见的话，会取消审稿吗？取消后还会找其他人来审稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210909/7146f1426c1e49bbb98d94637759e71f/7d17fd3269ca410d895702092f504459.jpg, createdBy=ac155115075, createdName=一只虫虫, createdTime=Wed Apr 20 22:34:55 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213503, encodeId=58db1213503e6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫治疗 经验分享：26 Feb 2022 submitted 4 Apr 2022 interview review 21 Apr 2022 review finalized 22 Apr 2022 accepted 科研小白的第一篇SCI。两位审稿专家，第1位8条意见，第2位4条意见，建议刚开始推荐审稿人，减少分配审稿人的时间，希望大家都能如愿以偿！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed025273112, createdName=14828bdem32暂无昵称, createdTime=Fri Apr 22 19:59:27 CST 2022, time=2022-04-22, status=1, ipAttribution=)]

2021-09-27 华灯初上&

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：免疫;先天免疫
经验分享：给大家分享一下我的投稿 Received date: 23 Aug 2021 Editorial assignment start date: 23 Aug 2021 Independent review start date: 04 Sep 2021 Interactive review activated date: 11 Sep 2021 Review finalized date: 25 Sep 2021 Final validation date: 27 Sep 2021 27号接收的。从投稿到接收一个多月。编辑很负责，外审专家提的意见也很中肯，稍微补了点实验，两轮修改之后接收。

113 15

展开15条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092291, encodeId=dacb20922915f, content=这个杂志吃相有点难看了，今年发文量已经9000篇，大概率要进年底的中科院预警, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Fri Oct 07 15:59:52 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052882, encodeId=e2fb10528824a, content=偏重的研究方向：免疫 经验分享：有最近投这个杂志板块的吗？9月6日提交含原始数据后，过了12天了，还没有看到有EA（editor assignment）的消息。一般大概等多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9215432780, createdName=ms7000000299539143, createdTime=Sat Sep 18 20:25:24 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799157, encodeId=ba6be991570e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：请问各位大佬，交完出版费大概多久见刊呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92185275664, createdName=14830f0fm18(暂无昵称), createdTime=Fri Jun 19 11:56:42 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009867, encodeId=2723100986ea9, content=我想问一下大家，Independent Review时，下面出现的那个review is onging代表什么，我的已经出现了两次了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Sat Aug 21 01:00:16 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217603, encodeId=6a20121e60358, content=偏重的研究方向：自身免疫 经验分享：重新提交原始数据之后一直处于初始阶段，老铁们，这大概要持续多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Sat May 07 12:41:08 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055459, encodeId=986e1055459c4, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫;先天免疫 经验分享：给大家分享一下我的投稿 Received date: 23 Aug 2021 Editorial assignment start date: 23 Aug 2021 Independent review start date: 04 Sep 2021 Interactive review activated date: 11 Sep 2021 Review finalized date: 25 Sep 2021 Final validation date: 27 Sep 2021 27号接收的。从投稿到接收一个多月。编辑很负责，外审专家提的意见也很中肯，稍微补了点实验，两轮修改之后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04235081194, createdName=华灯初上&, createdTime=Mon Sep 27 19:44:41 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198618, encodeId=6492119861813, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：抗病毒免疫 经验分享：三个审稿人，两个直接endorsed，一个直接rejected，从3. Independent Review直接跳到5. Review Finalized，都没有4. Interactive Review阶段。现在状态The Associate Editor is evaluating any revisions made to the manuscript to take a final decision.这个杂志审稿这么刺激啊，真是尴尬啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Wed Mar 02 10:05:47 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192212, encodeId=53a31192212da, content=各位友友，这个杂志还收不收纯生信呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/1d3a85981f6341c685aa69f9c27013bd/bc9a63edcff04dfda9c41946c5223f0b.jpg, createdBy=c7c95614650, createdName=ms2000001076054986, createdTime=Fri Feb 11 10:05:04 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212988, encodeId=70ff1212988fa, content=偏重的研究方向：免疫;肿瘤 经验分享：请问各位，目前是返修状态，返修4.24到期，一共五个审稿人，一个是rejected，一个endorsed，一个active，两个pending（4月20号到期），如果我21号提交修回稿件之后，这两个人还没有给意见的话，会取消审稿吗？取消后还会找其他人来审稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210909/7146f1426c1e49bbb98d94637759e71f/7d17fd3269ca410d895702092f504459.jpg, createdBy=ac155115075, createdName=一只虫虫, createdTime=Wed Apr 20 22:34:55 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213503, encodeId=58db1213503e6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫治疗 经验分享：26 Feb 2022 submitted 4 Apr 2022 interview review 21 Apr 2022 review finalized 22 Apr 2022 accepted 科研小白的第一篇SCI。两位审稿专家，第1位8条意见，第2位4条意见，建议刚开始推荐审稿人，减少分配审稿人的时间，希望大家都能如愿以偿！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed025273112, createdName=14828bdem32暂无昵称, createdTime=Fri Apr 22 19:59:27 CST 2022, time=2022-04-22, status=1, ipAttribution=)]

2022-03-02 南大

审稿速度:3.0 | 投稿命中率:25.0
偏重的研究方向：抗病毒免疫
经验分享：三个审稿人，两个直接endorsed，一个直接rejected，从3. Independent Review直接跳到5. Review Finalized，都没有4. Interactive Review阶段。现在状态The Associate Editor is evaluating any revisions made to the manuscript to take a final decision.这个杂志审稿这么刺激啊，真是尴尬啊

1 15

展开15条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092291, encodeId=dacb20922915f, content=这个杂志吃相有点难看了，今年发文量已经9000篇，大概率要进年底的中科院预警, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Fri Oct 07 15:59:52 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052882, encodeId=e2fb10528824a, content=偏重的研究方向：免疫 经验分享：有最近投这个杂志板块的吗？9月6日提交含原始数据后，过了12天了，还没有看到有EA（editor assignment）的消息。一般大概等多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9215432780, createdName=ms7000000299539143, createdTime=Sat Sep 18 20:25:24 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799157, encodeId=ba6be991570e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：请问各位大佬，交完出版费大概多久见刊呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92185275664, createdName=14830f0fm18(暂无昵称), createdTime=Fri Jun 19 11:56:42 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009867, encodeId=2723100986ea9, content=我想问一下大家，Independent Review时，下面出现的那个review is onging代表什么，我的已经出现了两次了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Sat Aug 21 01:00:16 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217603, encodeId=6a20121e60358, content=偏重的研究方向：自身免疫 经验分享：重新提交原始数据之后一直处于初始阶段，老铁们，这大概要持续多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Sat May 07 12:41:08 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055459, encodeId=986e1055459c4, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫;先天免疫 经验分享：给大家分享一下我的投稿 Received date: 23 Aug 2021 Editorial assignment start date: 23 Aug 2021 Independent review start date: 04 Sep 2021 Interactive review activated date: 11 Sep 2021 Review finalized date: 25 Sep 2021 Final validation date: 27 Sep 2021 27号接收的。从投稿到接收一个多月。编辑很负责，外审专家提的意见也很中肯，稍微补了点实验，两轮修改之后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04235081194, createdName=华灯初上&, createdTime=Mon Sep 27 19:44:41 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198618, encodeId=6492119861813, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：抗病毒免疫 经验分享：三个审稿人，两个直接endorsed，一个直接rejected，从3. Independent Review直接跳到5. Review Finalized，都没有4. Interactive Review阶段。现在状态The Associate Editor is evaluating any revisions made to the manuscript to take a final decision.这个杂志审稿这么刺激啊，真是尴尬啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Wed Mar 02 10:05:47 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192212, encodeId=53a31192212da, content=各位友友，这个杂志还收不收纯生信呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/1d3a85981f6341c685aa69f9c27013bd/bc9a63edcff04dfda9c41946c5223f0b.jpg, createdBy=c7c95614650, createdName=ms2000001076054986, createdTime=Fri Feb 11 10:05:04 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212988, encodeId=70ff1212988fa, content=偏重的研究方向：免疫;肿瘤 经验分享：请问各位，目前是返修状态，返修4.24到期，一共五个审稿人，一个是rejected，一个endorsed，一个active，两个pending（4月20号到期），如果我21号提交修回稿件之后，这两个人还没有给意见的话，会取消审稿吗？取消后还会找其他人来审稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210909/7146f1426c1e49bbb98d94637759e71f/7d17fd3269ca410d895702092f504459.jpg, createdBy=ac155115075, createdName=一只虫虫, createdTime=Wed Apr 20 22:34:55 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213503, encodeId=58db1213503e6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫治疗 经验分享：26 Feb 2022 submitted 4 Apr 2022 interview review 21 Apr 2022 review finalized 22 Apr 2022 accepted 科研小白的第一篇SCI。两位审稿专家，第1位8条意见，第2位4条意见，建议刚开始推荐审稿人，减少分配审稿人的时间，希望大家都能如愿以偿！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed025273112, createdName=14828bdem32暂无昵称, createdTime=Fri Apr 22 19:59:27 CST 2022, time=2022-04-22, status=1, ipAttribution=)]

2022-02-11 ms2000001076054986

各位友友，这个杂志还收不收纯生信呢？

83 15

展开15条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092291, encodeId=dacb20922915f, content=这个杂志吃相有点难看了，今年发文量已经9000篇，大概率要进年底的中科院预警, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Fri Oct 07 15:59:52 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052882, encodeId=e2fb10528824a, content=偏重的研究方向：免疫 经验分享：有最近投这个杂志板块的吗？9月6日提交含原始数据后，过了12天了，还没有看到有EA（editor assignment）的消息。一般大概等多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9215432780, createdName=ms7000000299539143, createdTime=Sat Sep 18 20:25:24 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799157, encodeId=ba6be991570e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：请问各位大佬，交完出版费大概多久见刊呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92185275664, createdName=14830f0fm18(暂无昵称), createdTime=Fri Jun 19 11:56:42 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009867, encodeId=2723100986ea9, content=我想问一下大家，Independent Review时，下面出现的那个review is onging代表什么，我的已经出现了两次了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Sat Aug 21 01:00:16 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217603, encodeId=6a20121e60358, content=偏重的研究方向：自身免疫 经验分享：重新提交原始数据之后一直处于初始阶段，老铁们，这大概要持续多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Sat May 07 12:41:08 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055459, encodeId=986e1055459c4, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫;先天免疫 经验分享：给大家分享一下我的投稿 Received date: 23 Aug 2021 Editorial assignment start date: 23 Aug 2021 Independent review start date: 04 Sep 2021 Interactive review activated date: 11 Sep 2021 Review finalized date: 25 Sep 2021 Final validation date: 27 Sep 2021 27号接收的。从投稿到接收一个多月。编辑很负责，外审专家提的意见也很中肯，稍微补了点实验，两轮修改之后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04235081194, createdName=华灯初上&, createdTime=Mon Sep 27 19:44:41 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198618, encodeId=6492119861813, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：抗病毒免疫 经验分享：三个审稿人，两个直接endorsed，一个直接rejected，从3. Independent Review直接跳到5. Review Finalized，都没有4. Interactive Review阶段。现在状态The Associate Editor is evaluating any revisions made to the manuscript to take a final decision.这个杂志审稿这么刺激啊，真是尴尬啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Wed Mar 02 10:05:47 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192212, encodeId=53a31192212da, content=各位友友，这个杂志还收不收纯生信呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/1d3a85981f6341c685aa69f9c27013bd/bc9a63edcff04dfda9c41946c5223f0b.jpg, createdBy=c7c95614650, createdName=ms2000001076054986, createdTime=Fri Feb 11 10:05:04 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212988, encodeId=70ff1212988fa, content=偏重的研究方向：免疫;肿瘤 经验分享：请问各位，目前是返修状态，返修4.24到期，一共五个审稿人，一个是rejected，一个endorsed，一个active，两个pending（4月20号到期），如果我21号提交修回稿件之后，这两个人还没有给意见的话，会取消审稿吗？取消后还会找其他人来审稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210909/7146f1426c1e49bbb98d94637759e71f/7d17fd3269ca410d895702092f504459.jpg, createdBy=ac155115075, createdName=一只虫虫, createdTime=Wed Apr 20 22:34:55 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213503, encodeId=58db1213503e6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫治疗 经验分享：26 Feb 2022 submitted 4 Apr 2022 interview review 21 Apr 2022 review finalized 22 Apr 2022 accepted 科研小白的第一篇SCI。两位审稿专家，第1位8条意见，第2位4条意见，建议刚开始推荐审稿人，减少分配审稿人的时间，希望大家都能如愿以偿！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed025273112, createdName=14828bdem32暂无昵称, createdTime=Fri Apr 22 19:59:27 CST 2022, time=2022-04-22, status=1, ipAttribution=)]

2022-04-20 一只虫虫

偏重的研究方向：免疫;肿瘤
经验分享：请问各位，目前是返修状态，返修4.24到期，一共五个审稿人，一个是rejected，一个endorsed，一个active，两个pending（4月20号到期），如果我21号提交修回稿件之后，这两个人还没有给意见的话，会取消审稿吗？取消后还会找其他人来审稿吗？

98 15

展开15条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092291, encodeId=dacb20922915f, content=这个杂志吃相有点难看了，今年发文量已经9000篇，大概率要进年底的中科院预警, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/AC155882450E4EC1FD036F717D37D497/100, createdBy=ba642497095, createdName=H·D·E, createdTime=Fri Oct 07 15:59:52 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052882, encodeId=e2fb10528824a, content=偏重的研究方向：免疫 经验分享：有最近投这个杂志板块的吗？9月6日提交含原始数据后，过了12天了，还没有看到有EA（editor assignment）的消息。一般大概等多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9215432780, createdName=ms7000000299539143, createdTime=Sat Sep 18 20:25:24 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799157, encodeId=ba6be991570e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：请问各位大佬，交完出版费大概多久见刊呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92185275664, createdName=14830f0fm18(暂无昵称), createdTime=Fri Jun 19 11:56:42 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009867, encodeId=2723100986ea9, content=我想问一下大家，Independent Review时，下面出现的那个review is onging代表什么，我的已经出现了两次了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3f45535257, createdName=骞骞F文章, createdTime=Sat Aug 21 01:00:16 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217603, encodeId=6a20121e60358, content=偏重的研究方向：自身免疫 经验分享：重新提交原始数据之后一直处于初始阶段，老铁们，这大概要持续多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201020/ab7dee8018d2436d9c185605ca6df4d1/259e5aca63734597994109f6badb5036.jpg, createdBy=e5255379558, createdName=丿柚子, createdTime=Sat May 07 12:41:08 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055459, encodeId=986e1055459c4, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫;先天免疫 经验分享：给大家分享一下我的投稿 Received date: 23 Aug 2021 Editorial assignment start date: 23 Aug 2021 Independent review start date: 04 Sep 2021 Interactive review activated date: 11 Sep 2021 Review finalized date: 25 Sep 2021 Final validation date: 27 Sep 2021 27号接收的。从投稿到接收一个多月。编辑很负责，外审专家提的意见也很中肯，稍微补了点实验，两轮修改之后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=04235081194, createdName=华灯初上&, createdTime=Mon Sep 27 19:44:41 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198618, encodeId=6492119861813, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：抗病毒免疫 经验分享：三个审稿人，两个直接endorsed，一个直接rejected，从3. Independent Review直接跳到5. Review Finalized，都没有4. Interactive Review阶段。现在状态The Associate Editor is evaluating any revisions made to the manuscript to take a final decision.这个杂志审稿这么刺激啊，真是尴尬啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Wed Mar 02 10:05:47 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192212, encodeId=53a31192212da, content=各位友友，这个杂志还收不收纯生信呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/1d3a85981f6341c685aa69f9c27013bd/bc9a63edcff04dfda9c41946c5223f0b.jpg, createdBy=c7c95614650, createdName=ms2000001076054986, createdTime=Fri Feb 11 10:05:04 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212988, encodeId=70ff1212988fa, content=偏重的研究方向：免疫;肿瘤 经验分享：请问各位，目前是返修状态，返修4.24到期，一共五个审稿人，一个是rejected，一个endorsed，一个active，两个pending（4月20号到期），如果我21号提交修回稿件之后，这两个人还没有给意见的话，会取消审稿吗？取消后还会找其他人来审稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210909/7146f1426c1e49bbb98d94637759e71f/7d17fd3269ca410d895702092f504459.jpg, createdBy=ac155115075, createdName=一只虫虫, createdTime=Wed Apr 20 22:34:55 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213503, encodeId=58db1213503e6, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫治疗 经验分享：26 Feb 2022 submitted 4 Apr 2022 interview review 21 Apr 2022 review finalized 22 Apr 2022 accepted 科研小白的第一篇SCI。两位审稿专家，第1位8条意见，第2位4条意见，建议刚开始推荐审稿人，减少分配审稿人的时间，希望大家都能如愿以偿！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed025273112, createdName=14828bdem32暂无昵称, createdTime=Fri Apr 22 19:59:27 CST 2022, time=2022-04-22, status=1, ipAttribution=)]

2022-04-22 14828bdem32暂无昵称

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：免疫治疗
经验分享：26 Feb 2022 submitted 4 Apr 2022 interview review 21 Apr 2022 review finalized 22 Apr 2022 accepted 科研小白的第一篇SCI。两位审稿专家，第1位8条意见，第2位4条意见，建议刚开始推荐审稿人，减少分配审稿人的时间，希望大家都能如愿以偿！

62 15

展开15条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务